Synonym
CMV-423; CMV423; CMV 423; RPR-111423;
IUPAC/Chemical Name
2-chloro-3-(pyridin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
InChi Key
KNGXENHWYNLKBU-UHFFFAOYSA-N
InChi Code
1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19)
SMILES Code
NC(=O)C1=C2CCCCN2C(=C1Cl)C3=CC=CN=C3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
275.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Perrin MA. Cristallographie du polymorphisme des médicaments: émergence de nouvelles méthodes de résolution et de prédiction de structures cristallines [Crystallography of drug polymorphism: emergence of new resolution methods and prediction of crystalline structures]. Ann Pharm Fr. 2002 May;60(3):187-202. French. PMID: 12050597.
2: Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, de Clercq E, Neyts J, Schols D, Naesens L, Michelson S, Bron D, Otto MJ, Bousseau A, Nemecek C, Roy C. 2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res. 2002 Sep;55(3):413-24. doi: 10.1016/s0166-3542(02)00074-8. PMID: 12206879.
3: Bournique B, Lambert N, Boukaiba R, Martinet M. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). Br J Clin Pharmacol. 2001 Jul;52(1):53-63. doi: 10.1046/j.0306-5251.2001.01413.x. PMID: 11453890; PMCID: PMC2014500.
4: De Bolle L, Andrei G, Snoeck R, Zhang Y, Van Lommel A, Otto M, Bousseau A, Roy C, De Clercq E, Naesens L. Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol. 2004 Jan 15;67(2):325-36. doi: 10.1016/j.bcp.2003.08.042. PMID: 14698045.
